The FDA alerted pharmaceutical companies that it will hold them accountable for the advertising and marketing activities of their subsidiaries, including pharmacy benefit management companies.
The FDA alerted pharmaceutical companies that it will hold them accountable for the advertising and marketing activities of their subsidiaries, including pharmacy benefit management companies.
Under the guidelines, PBMs must submit copies of all advertisements, brochures and other promotional materials for FDA review.
In its proposed guidance for industry, the FDA stated: "Generally, a medical product sponsor will be held responsible for promotional activities performed by its health care organization or PBM subsidiary that violate the act or regulations (e.g., the dissemination of false or misleading labeling or advertising). Promotional labeling and advertising disseminated by the subsidiary are subject to the existing post-marketing reporting requirements."
In the past, the FDA has not regulated the promotional practices of PBMs because their traditional role was to manage health care costs. However, recent marriages between several PBMs and large pharmaceutical manufacturers have raised concerns at the FDA.
One major concern is that pharmaceutical manufacturers could use their clout to influence which prescription products their affiliated PBMs select and market to health care-purchasing customers.
Pharmaceutical companies that lack similar relationships have complained that the pairings create an unfair marketing and promotional loophole.
In its guidance, the FDA acknowledged that it "generally does not exercise jurisdiction over materials disseminated by individuals or entities that are not in any way affiliated with a medical product sponsor." However, the agency continued, "the sponsor should not be permitted to avoid regulations by changing the form through which their communication is accomplished."
The FDA said it would allow for a 90-day comment period before issuing a final guidance. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.